

Synthesis and Antimicrobial Activity of Cyclic Dithiocarbamates Employing Triton-B/CS₂ System

RISHI KUMAR VISHNOI¹, SANGEETA BAJPAI^{1,*,©}, Devdutt Chaturvedi^{2,*,©}, Manisha Shukla³, Ram Kishore¹ and Nitin Srivastava^{1,©}

¹Department of Chemistry, Amity University Uttar Pradesh, Lucknow Campus, Lucknow-226028, India ²Department of Chemistry, School of Physical Sciences, Mahatma Gandhi Central University, Motihari-845401, India ³Department of Chemistry, Babu Banarasi Das National Institute of Technology & Management, Lucknow-227105, India

*Corresponding author: E-mail: devduttchaturvedi@gmail.com; sbajpail@amity.edu

Received: 18 February 2021;	Accepted: 17 March 2021;	Published online: 16 April 2021;	AJC-20335
-----------------------------	--------------------------	----------------------------------	-----------

An efficient and green methodology to synthesize cyclic dithiocarbamates (compounds 1-11) was developed by reaction of primary amines, CS_2 and 1,2-dibromoethane or 1,4-dibromobutane, catalyzed by Triton-B (as PTC)/ CS_2 system. Mass spectroscopy, elemental analysis and ¹H NMR are used for characterization of the synthesized compounds (1-11). This effectual green tactics give good yield of product which entails mild conditions. Compounds (1-11) were found to possess *in vitro* antimicrobial activities against the pathogenic bacterial and fungal strain. The microbial strains used to screen activities are *Escherichia coli*, *Staphylococcus aureus* and *Candida albicans*.

Keywords: Primary amine, Dithiocarbamates, Dihaloalkane, Triton-B, Biological activities.

INTRODUCTION

Cyclic dithiocarbamates are important class of organosulfur compounds that display plethora of important applications such as pharmaceuticals and agrochemicals [1-4], insecticide and worldwide as crop protection pest controls (thiacloprid) [5], numerous analogous [6], antiproliferative [7], hypertension and hyperlipidemia [8], analgesic and antiparkinsonian activity [9], antioxidants [10], transient receptor potential vanilloid 1 (TRPV-1) [11], pesticides [12], central nervous systems [13], anti-inflammatory (COX-2 inhibitor) and ulcerogenic activity [14,15], antibacterial [16], antidiabetic [17], antifungal [18], anti-HIV [19], oncological activity [20], antitumor [21], tyrosine inhibitor [22], antibiofilm [23], anticonvulsant [24], wound healing [25], phyto-growth inhibitory [26], antihyperglycemic [27], fungicidal activity [28] and group transfer radical cyclization reactions [29], etc. Furthermore, transition metals complexes of dithiocarbamates have been stated for many reviews since they are used as organic superconductors [30]. Organic cyclic dithiocarbamates had been used for facile and versatile synthesis [31-41] and well-thought-out as significant biological moiety. Cyclic dithiocarbamates are evaluated for their toxicological activity [42]. Traditionally, toxic chemicals such as phosgene, thiophosgene and its byproducts are used to prepare

organic cyclic dithiocarbamates but this is time taking method and require high temperature. Different effectual green methods are designated in literature to produce cyclic dithiocarbamates. In recent years, our research group has been realized that benzyl trimethylammonium hydroxide (Triton-B) has been used even as emerging catalyst for facile synthesis of numerous organic compounds [43-47]. We have also synthesized various kinds of dithiocarbamate employing CS₂/Triton-B system from variety of starting materials [48]. In this article, thiazolidine-2-thiones were synthesized starting with the corresponding dihaloalkane, 1° amines employing Triton-B/CS₂ system and the synthesized compounds have been assessed by antimicrobial activity.

EXPERIMENTAL

Chemicals bought from Alfa-Aesar, GLR, Lobachem, AVRA and Finar, Labchem. MB-104-FTIR spectrophotometer of ABB Bomem, was used for recording infrared spectra (4000-200cm⁻¹). The AC-400F-nuclear magnetic resonance spectrometer with tetramethyl silane as internal standard was used for recording ¹H NMR spectra at 400 MHz. The examinations of elements were conveyed with the help of a 1110-CNNO-S (Carlo-ErbaEA) analyzer.

This is an open access journal, and articles are distributed under the terms of the Attribution 4.0 International (CC BY 4.0) License. This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit the author for the original creation. You must give appropriate credit, provide a link to the license, and indicate if changes were made.

Asian J. Chem.

General protocol: Primary amine (1 mmol) in DMSO and 10 mmol of CS_2 was stirred for 15 min after adding 3 mmol of Triton-B as phase transfer catalyst. The reaction mass was again stirred for 10 min after adding (1,2-dibromoethane or 1,4-dibromobutane) dropwise under argon atmosphere. The reacting mixture was stirred at room temperature for 1-2 h. The reaction mixture was monitored by TLC. After completion the reaction mass was quenched with 50 mL distilled H₂O and pull out with ethyl acetate thrice. The layer of organic compound was separated and dried by anhydrous Na₂SO₄ and concentrated to get the crude compound, using silica-gel (100-200 mesh) and eluent 20% (ethylacetate: hexane) to give the desired product.

3-Phenyl-1,3-thiazepane-2-thione (1): Yellow solid, m.p.: 62 °C. Elemental analysis of $C_{11}H_{13}NS_2$ calcd. (found) (%): C, 59.15 (59.35); H, 5.87 (5.95); N, 6.27 (6.32); S, 28.71 (28.95). ¹H NMR (400 MHz, CDCl₃, δ ppm): 7.429-7.317 (m, 5H), 3.328 (m, 4H), 1.824 (m, 4H). MS (ESI): *m/z* (M)⁺ calculated = 223.05, Found (M+1)⁺ = 223.36.

3-Heptyl-1,3-thiazepane-2-thione (2): Yellow solid, m.p.: 67 °C. Elemental analysis of C₁₂H₂₃NS₂ calcd. (found) (%): C, 58.72 (58.95); H, 9.45 (9.65); N, 5.71 (5.85); S, 26.13 (26.45). ¹H NMR (400 MHz, CDCl₃, δ ppm): 3.348 (t, *J* = 7.2 Hz, 2H), 3.137 (d, *J* = 5.6 Hz, 2H), 3.017 (d, *J* = 5.6 Hz, 2H), 2.256-2.210 (m, 4H), 1.654 (m, 2H), 1.425-1.213 (m, 8H), 0.875 (t, *J* = 6.4 Hz, 3H). MS (ESI): *m/z* (M)⁺ calculated = 245.15, Found (M+1)⁺= 245.45.

3-(2,4-Dichlorobenzyl)-1,3-thiazepane-2-thione (3): Yellow solid, m.p.: 121 °C. Elemental analysis of $C_{12}H_{13}NS_2Cl_2$ calcd. (found) (%): C, 47.06 (47.25); H, 4.28 (4.32); Cl, 23.15 (23.35); N, 4.57 (4.87); S, 20.94 (21.14). ¹H NMR (400 MHz, CDCl₃, δ ppm): 7.462-7.385 (m, 2H), 7.260 (s, 1H), 4.984 (t, J = 5.6 Hz, 2H), 4.173 (s, 2H), 3.429 (q, J = 6.8 Hz, 2H), 3.305 (q, J = 6.8 Hz, 2H), 3.159 (t, J = 5.6 Hz, 2H). MS (ESI): m/z (M)⁺ calculated = 304.99, Found (M+1)⁺= 306.27.

3-(2,4-Dichlorobenzyl)thiazolidine-2-thione (4): Yellow solid, m.p.: 93 °C. Elemental analysis of $C_{10}H_9NS_2Cl_2$ calcd. (found) (%): C, 43.17 (43.43); H, 3.26 (3.45); Cl, 25.49 (25.58); N, 5.03 (5.13); S, 23.05 (23.45). ¹H NMR (400 MHz, CDCl₃, δ ppm): 7.453 (d, *J* = 8.0 Hz, 1H), 7.368 (s, 1H), 7.230 (t, *J* = 5.6 Hz, 2H), 3.466 (t, *J* = 5.6 Hz, 2H). MS (ESI): *m/z* (M)⁺ calculated = 276.96, Found (M+1)⁺ = 278.22.

3-(3-Fluorobenzyl)thiazolidine-2-thione (5): Yellow solid, m.p.: 98 °C. Elemental analysis of $C_{10}H_{10}NS_2F$ calcd. (found) (%): C, 52.84 (52.94); H, 4.43 (4.53); F, 8.36 (8.52); N, 6.16 (6.35); S, 28.21 (28.43). ¹H NMR (400 MHz, CDCl₃, δ ppm): 7.626-7.308 (m, 2H), 7.129-7.026 (m, 3H), 4.926 (s, 2H), 3.957 (t, *J* = 8.4 Hz, 2H), 3.263 (t, *J* = 8.0 Hz, 2H). MS (ESI): *m/z* (M)⁺ calculated = 227.02, Found (M+1)⁺ = 227.32.

3-(3-Fluorobenzyl)-1,3-thiazepane-2-thione (6): Yellow solid, m.p.: 98 °C. Elemental analysis of $C_{12}H_{14}NS_2F$ calcd. (found) (%): C, 56.44 (56.62); H, 5.53 (5.68); F, 7.44 (7.72); N, 5.48 (5.92); S, 25.11 (25.98). ¹H NMR 400 MHz, CDCl₃, δ ppm: 7.337-7.280 (m, 2H), 7.207-6.975 (m, 3H), 4.929 (s, 2H), 3.440 (t, *J* = 6.4 Hz, 2H), 3.389-3.268 (m, 4H), 3.150 (t, *J* = 5.2 Hz, 2H). MS (ESI): *m/z* (M)⁺ calculated = 255.06, Found (M+1)⁺ = 255.36.

3-(3-Fluorophenylethyl)-1,3-thiazepane-2-thione (7): Yellow solid, m.p.: 82 °C. Elemental analysis of $C_{13}H_{16}NS_2F$ calcd. (found) %: C, 57.96 (58.26); H, 5.99 (6.56); F, 7.05 (7.35); N, 5.20 (5.43); S, 23.80 (23.98).¹H NMR (400 MHz, CDCl₃, δ ppm): 7.519 (s, 1H), 7.038-6.914 (m, 3H), 3.966 (q, J = 6.8 Hz, 2H), 3.392-3.283 (m, 4H), 2.978 (t, J = 6.4 Hz, 2H), 1.834-1.784 (m, 4H). MS (ESI): m/z (M)⁺ calculated = 269.06, Found (M+1)⁺ = 269.40.

3-(4-Methoxy-phenylethyl)-1,3-thiazepane-2-thione (8): Yellow solid, m.p.: 82 °C. Elemental analysis of $C_{13}H_{16}NS_2F$ calcd. (found) %: C, 59.75 (59.86); H, 6.80 (6.96); N, 4.98 (5.45); O, 5.68 (5.79), S, 22.79 (22.98). ¹H NMR (400 MHz, CDCl₃, δ ppm): 7.125 (d, J = 8.0 Hz, 2H), 6.876 (d, J = 8.4 Hz, 2H), 3.955 (q, J = 6.4 Hz, 2H), 3.798 (s, 3H), 3.390-3.267 (m, 4H), 2.909 (t, J = 6.8 Hz, 2H), 1.820-1.770 (m, 4H). MS (ESI): m/z (M)⁺ calculated = 281.09, Found (M+1)⁺= 281.44.

3-(2,4-Difluorobenzyl)thiazolidine-2-thione (9): Yellow solid, m.p.: 87 °C. Elemental analysis of $C_{10}H_9NS_2F_2$ calcd. (found) %: C, 48.96 49.13); H, 3.70 (3.89); F, 15.49 (15.75); N, 5.71 (5.91); S, 26.14 (26.64). ¹H NMR (400 MHz, CDCl₃, δ ppm): 7.410 (t, J = 7.2 Hz, 1H), 7.128 (s, 1H), 6.883-6.814 (m, 2H), 4.935 (s, 2H), 3.361 (t, J = 8.0 Hz, 2H), 1.799 (t, J = 8.0 Hz, 2H). MS (ESI): m/z (M)⁺ calculated = 245.01, Found (M+1)⁺ = 245.31.

3-(3-Bromo-phenylethyl)-1,3-thiazepane-2-thione (10): Yellow solid, m.p.: 64 °C. Elemental analysis of $C_{13}H_{16}NS_2Br$, calcd. (found) %: C, 47.27 (47.52); H, 4.88 (4.98); Br, 24.19 (24.59); N, 4.24 (4.98); S, 19.42 (19.73). ¹H NMR (400 MHz, CDCl₃, δ ppm): 7.632-7.369 (m, 2H), 7.198 (t, J = 7.6 Hz, 1H), 7.151 (d, J = 7.6 Hz, 1H), 3.968 (q, J = 6.8 Hz, 2H), 3.393 (m, 4H), 2.974 (t, J = 6.8 Hz, 2H), 1.821-1.788 (m, 4H). MS (ESI): m/z (M)⁺ calculated = 328.99, Found (M+1)⁺= 330.31.

3-(2-Methylbenzyl)thiazolidine-2-thione (11): Yellow solid, m.p.: 67 °C. Elemental analysis of C₁₁H₁₃NS₂ calcd. (found) (%): C, 59.15 (59.43); H, 5.87 (5.95); N, 6.27 (6.87); S, 28.71 (28.88). ¹H NMR (400 MHz) (CDCl₃): δ 7.442-7.310 (m, 1H), 7.223-6.392 (m, 3H), 4.464 (s, 2H), 3.620 (t, *J* = 6.4 Hz, 2H), 3.436 (t, *J* = 5.6 Hz, 2H), 2.331 (s, 3H).MS (ESI): *m/z* (M)⁺ calculated = 223.06, Found (M+1)⁺= 223.36.

RESULTS AND DISCUSSION

Three components primary amines (1), $CS_2(2)$ with 1, 2dibromoethane or 1,4-dibromobutane (3) and Triton-B catalyst were reacted in DMSO at room temperature to produce thiazolidine-2-thiones or thiazepane-2-thione (4) to get good yields (Table-1). The CS_2 mediated synthesis is described for the synthesis of a large number of cyclic dithiocarbamates derivatives and offers some notable and distinct advantages over usually employed procedure such as simplicity, room temperature conditions, simple work-up, high yield and cheap reagent.

The synthesized compounds were found to be soluble in methanol, acetone, ethanol, ethyl acetate, dichloromethane, diethylether, DMF, CDCl₃, *etc.* The confirmation of product formation was done with the mass spectroscopy and¹H NMR. Different phase transfer catalysts (PTC) are commonly used for the synthesis but Triton-B is preferable than other PTC due to high yields of the product [49].

SYNTHESIS OF THIAZOLIDINE-2-THIONE OR 1,3- THIAZEPANE-2-THIONE CATALYZED BY TRITON-B						
Compd. No.	Substituted R ₁	m.f.	m.w.	Yield (%)		
1	Phenyl	$C_{11}H_{13}NS_2$	223.36	94.23		
2	Heptyl	$C_{12}H_{23}NS_2$	245.45	95.45		
3	2,4-Cl ₂ -benzyl	$C_{12}H_{13}NS_2Cl_2$	306.27	93.26		
4	2,4-Cl ₂ -benzyl	$C_{10}H_9NS_2Cl_2$	278.22	93.56		
5	3-F-benzyl	$C_{10}H_{10}NS_2F$	227.32	94.45		
6	3-F-benzyl	$C_{12}H_{14}NS_2F$	255.37	94.58		
7	3-F-phenyethyl	$C_{13}H_{16}NS_2F$	269.40	93.98		
8	4-CH ₃ O-phenylethyl	$C_{13}H_{16}NS_2F$	281.44	94.98		
9	2,4-F ₂ benzyl	$C_{10}H_9NS_2F_2$	245.31	93.95		
10	3-Br-phenylethyl	$C_{13}H_{16}NS_2Br$	330.31	94.36		
11	2-CH ₃ -benzyl	$C_{11}H_{13}NS_2$	223.36	90.52		

TABLE-1

The method is easier and requires simpler work-up using low cost less toxic reagents. Out-put of the product is improved and synthesized in lesser time. The compounds synthesized in this series were identified by ¹H NMR and mass spectra. The intermediate most probably results from addition of dithiocarbamate salt to dihaloalkane and subsequently intramolecular cyclization of the product (**Scheme-I**).

Antimicrobial activity: The derivatives were assessed for their antimicrobial activity against *Staphylococcus aureus*, *Escherichia coli* and *Candida albicans*. The antimicrobial assay was done by Agar-well diffusion method using Muller Hinton agar media for bacteria and Sabouraud Dextrose agar media for fungus. The examination was done using 1 mg/mL concentration of the synthesized derivatives in ethyl acetate as solvent. The antibiotic oxytetracycline and fluconazole were used as positive control for bacteria and fungus respectively. Some compounds showed the antimicrobial activity against the selected strain by the showing inhibition on the media. The zone of inhibition obtained is listed in Table-2.


TABLE-2 ZONE OF INHIBITION OF THE SYNTHESIZED COMPOUNDS FOR ANTIMICROBIAL ACTIVITY							
Compd. No.	Substituted R ₁	Zone of inhibition (mm)					
		S. aureus	E. coli	C. albicans			
1	Phenyl	20	17	14			
2	Heptyl	15	16	17			
3	2,4-Cl ₂ -benzyl	20	19	14			
4	2,4-Cl ₂ -benzyl	15	19	15			
5	3-F-benzyl	18	17	14			
6	3-F-benzyl	15	14	16			
7	3-F-phenyethyl	12	17	14			
8	4-CH ₃ O-phenylethyl	18	18	17			
9	2,4-F ₂ -benzyl	12	17	15			
10	3-Br-phenylethyl	18	16	17			
11	2-CH ₃ -benzyl	20	18	15			
12	(+) Control	25	22	25			
13	(-) Control	Nil	Nil	Nil			

Conclusion

In conclusion, a highly dexterous procedure was developed for the synthesis of cyclic dithiocabamates derivatives under the mild conditions using different primary amines with dihaloalkane via CS_2 /Triton-B system. The derivatives formed also showed the important biological activity as some of them were found to possess the antimicrobial activity against the bacterial and fungal strain. So, these compounds may be further sight seen for their *in vivo* antimicrobial activity.

ACKNOWLEDGEMENTS

This study was assisted with infrastructural support by Department of Chemistry, Amity University Uttar Pradesh Lucknow Campus, Lucknow, India.



Scheme-I: Synthesis of thiazolidine-2-thione or 1,3-thiazepane-2-thione catalyzed by Triton-B

CONFLICT OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this article.

REFERENCES

- S.L. Cao, Y. Han, C.Z. Yuan, Y. Wang, J.K. Xiahou, J. Liao, R.T. Gao, B.B. Mao, B.L. Zhao, J.F. Li and X. Xu, *Eur. J. Med. Chem.*, **64**, 401 (2013);
- https://doi.org/10.1016/j.ejmech.2013.04.017 2. B. Cvek and Z. Dvorak, *Curr. Pharm. Des.*, **13**, 3155 (2007); https://doi.org/10.2174/138161207782110390
- O. Guzel and A. Salman, *Bioorg. Med. Chem.*, 14, 7804 (2006); https://doi.org/10.1016/j.bmc.2006.07.065
- Y. Qian, J.Y. Ma, Y. Yang, K. Cheng, Q.Z. Zheng, W.J. Mao, L. Shi, J. Zhao and H.L. Zhu, *Bioorg. Med. Chem.*, 18, 4310 (2010); <u>https://doi.org/10.1016/j.bmc.2010.04.091</u>
- P. Jeschke, K. Moriya, R. Lantzsch, H. Seifert, W. Lindner, K. Jelich, A. Göhrt, M.E. Beck and W. Etzel, A New Member of the Chloronicotinyl Insecticide (CNI) Family, *Pflanzenschutz-Nachr. Bayer*, 54, 147 (2001).
- L. Novák, G. Hornyánszky, I. Király, J. Rohály, P. Kolonits and C. Szántay, *Heterocycles*, 55, 45 (2001); https://doi.org/10.3987/COM-00-9016
- Y. Zhang, B. Liu, X. Wu, R. Li, X. Ning, Y. Liu, Z. Liu, Z. Ge, R. Li and Y. Yin, *Bioorg. Med. Chem.*, 23, 4815 (2015); <u>https://doi.org/10.1016/j.bmc.2015.05.041</u>
- C.H. Lee, Y.S. Jung, H.J. Yang, Y.J. Son and S.H. Lee, *Acta Neurochir.*, 154, 67 (2012);
- https://doi.org/10.1007/s00701-011-1212-1 9. E.E. Flefel, M.A. Salama, M. El-Shahat, M.A. El-Hashash and A.F.
- E.E. Fletel, M.A. Salama, M. El-Shahal, M.A. El-Hashash and A.F El-Farargy, *Phosphorus Sulfur Silicon Rel. Elem.*, **182**, 1739 (2007); https://doi.org/10.1080/10426500701313912
- M. Said, K. Abouzid, A. Mouneer, A. Ahmedy and A.M. Osman, *Arch. Pharm. Res.*, **27**, 471 (2004); https://doi.org/10.1007/BF02980118
- B.J. Branstetter, J.G. Breitenbucher, A.D. Lebsack and W. Xiao, Thiazolopyrimidine Modulators of TRPV1, U.S. Patent WO 005303, (2008).
- 12. W. Linder, W. Brandes, Pesticidal Thiazolopyrimidine Derivatives, U.S. Patent 4996208 (1991).
- D. Havrylyuk, L. Mosula, B. Zimenkovsky, O. Vasylenko, A. Gzella and R. Lesyk, *Eur. J. Med. Chem.*, 45, 5012 (2010); https://doi.org/10.1016/j.ejmech.2010.08.008
- K.R.A. Abdellatif, M.A. Abdelgawad, H.A.H. Elshemy and S.S.R. Alsayed, *Bioorg. Med. Chem.*, 64, 1 (2016); <u>https://doi.org/10.1016/j.bioorg.2015.11.001</u>
- Y.L. Piao, A. Ram Song and H. Cho, *Bioorg. Med. Chem.*, 23, 2098 (2015); https://doi.org/10.1016/j.bmc.2015.03.010
- N.C. Desai, K. Rajpara and V.V. Joshi, J. Fluor. Chem., 145, 102 (2013); https://doi.org/10.1016/j.jfluchem.2012.10.012
- J. Choi, Y. Ko, H.S. Lee, Y.S. Park, Y. Yang and S. Yoon, *Eur. J. Med. Chem.*, 45, 193 (2010);
- https://doi.org/10.1016/j.ejmech.2009.09.042
- A. Dandia, R. Singh, S. Khaturia, C. Me'rienne, G. Morgant and A. Loupy, *Bioorg. Med. Chem.*, 14, 2409 (2006); https://doi.org/10.1016/j.bmc.2005.11.025
- R.K. Rawal, R. Tripathi, S.B. Katti, C. Pannecouque and E. De Clercq, *Bioorg. Med. Chem.*, **15**, 1725 (2007); <u>https://doi.org/10.1016/j.bmc.2006.12.003</u>
- K. Liu, W. Rao, H. Parikh, Q. Li, T.L. Guo, S. Grant, G.E. Kellogg and S. Zhang, *Eur. J. Med. Chem.*, 47, 125 (2012); https://doi.org/10.1016/j.ejmech.2011.10.031
- M.M. Kamel, H.I. Ali, M.M. Anwar, N.A. Mohamed and A.M.M. Soliman, *Eur. J. Med. Chem.*, 45, 572 (2010); https://doi.org/10.1016/j.ejmech.2009.10.044
- Y.H. Ha, Y.J. Park, J.Y. Lee, D. Park, Y.J. Choi, E.K. Lee, J.M. Kim, J.A. Kim, J.Y. Park, H.J. Lee, H.R. Moon and H.Y. Chung, *Biochimie*, 94, 533 (2012); https://doi.org/10.1016/j.biochi.2011.09.002

- B. Pan, R.Z. Huang, S.Q. Han, D. Qu, M.L. Zhu, P. Wei and H.J. Ying, Bioorg. Med. Chem. Lett., 20, 2461 (2010); https://doi.org/10.1016/j.bmcl.2010.03.013
- 24. R.M. Rohini and M. Manjunath, Der Pharma Chem., 4, 2438 (2012).
- 25. W. Eberhardt, D. Kunz and J. Pfeilschifter, *Biophys. Res. Commun.*, **200**, 163 (1994);
- https://doi.org/10.1006/bbrc.1994.1429 26. A.J. Overman and D.S. Burgis, *Proc. Florida Sta. Hart. Soc.*, **69**, 250
- A.J. Overman and D.S. Burgis, *Proc. Florida Sta. Hart. Soc.*, **69**, 250 (1956).
- U.S. Dighe, D.V. Yadav, R. Srivastava, A. Mishra, S. Gautam, A.K. Srivastava, V.M. Balaramnavar, A.K. Saxena and S. Batra, *Tetrahedron Lett.*, **70**, 6841 (2014); <u>https://doi.org/10.1016/j.tet.2014.07.044</u>
- N. Chen, H. Du, W. Liu, S. Wang, X. Li and J. Xu, *Phosphorus Sulfur Silicon Rel. Elem.*, **190**, 112 (2015); https://doi.org/10.1080/10426507.2014.931399
- R.S. Grainger and P. Innocenti, *Heteroatom Chem.*, 18, 568 (2007); https://doi.org/10.1002/hc.20336
- N. Alexander, K. Ramalingam and C. Rizzoli, *Inorg. Chim. Acta*, 365, 480 (2011);
- https://doi.org/10.1016/j.ica.2010.09.029 31. P. Liu, C. Li, J. Zhang and X. Xu, *Synth. Commun.*, **43**, 3342 (2013); https://doi.org/10.1080/00397911.2013.783600
- A.Z. Halimehjani, Y. Pourshojaei and M.R. Saidi, *Tetrahedron Lett.*, 50, 32 (2009);
- https://doi.org/10.1016/j.tetlet.2008.10.063 33. L. Jamir, U.B. Sinha, J. Nath and B.K. Patel, *Synth. Commun.*, **42**, 951 (2012);
 - https://doi.org/10.1080/00397911.2010.532276
- 34. M. Kienle, A. Unsinn and P. Knochel, *Angew. Chem. Int. Ed.*, **49**, 4751 (2010);
- https://doi.org/10.1002/anie.201001025 35. V. Aucagne, C. Lorin, A. Tatibouet and P. Rollin, *Tetrahedron Lett.*, **46**, 4349 (2005);
- https://doi.org/10.1016/j.tetlet.2005.04.112
 36. N.K. Kumar, K. Sreeramamurthy, S. Palle, K. Mukkanti and P. Das, *Tetrahedron Lett.*, **51**, 899 (2010);
- https://doi.org/10.1016/j.tetlet.2009.11.127
- M.A. Khalilzadeh, Z. Hossaini, M.M. Baradarani and A. Hasannia, *Tetrahedron Lett.*, 66, 8464 (2010); https://doi.org/10.1016/j.tet.2010.08.041
- S.K. Tandel, S. Rajappa and S.V. Pansare, *Tetrahedron Lett.*, **49**, 7479 (1993);
- https://doi.org/10.1016/S0040-4020(01)87224-0 39. F.R. Charati, J. Hossaini and R. Hajinasiri, *J. Appl. Chem. Res.*, **20**, 54
- (2012).
 40. L.J. Bahrin, P.J. Jones and H. Hopf, *Beilstein J. Org. Chem.*, 8, 1999 (2012);

https://doi.org/10.3762/bjoc.8.226

- 41. P.M. Madalageri and O. Kotresh, J. Chem. Pharm. Res., 4, 2697 (2012).
- K. Bacharaju, S.R. Jambula, S. Sivan, S. Jyostnatangeda and V. Manga, Bioorg. Med. Chem. Lett., 22, 3274 (2012); <u>https://doi.org/10.1016/j.bmcl.2012.03.018</u>
- D. Chaturvedi, A. Kumar and S. Ray, Synth. Commun., 32, 2651 (2002); https://doi.org/10.1081/SCC-120006028
- 44. D. Chaturvedi, A. Kumar and S. Ray, *Tetrahedron Lett.*, **44**, 7637 (2003); https://doi.org/10.1016/j.tetlet.2003.08.018
- 45. D. Chaturvedi and S. Ray, *Lett. Org. Chem.*, **2**, 742 (2005); https://doi.org/10.2174/157017805774717472
- D. Chaturvedi and S. Ray, J. Sulfur Chem., 26, 365 (2005); https://doi.org/10.1080/17415990500404848
- D. Chaturvedi and S. Ray, J. Sulfur Chem., 27, 265 (2006); https://doi.org/10.1080/17415990600701697
- R. Kishore, M. Kamboj, M. Shukla and N. Srivastava, *Asian J. Chem.*, 31, 1091 (2019);
- https://doi.org/10.14233/ajchem.2019.21830
- S. Zaidi, A.K. Chaturvedi, N. Singh and D. Chaturvedi, *Curr. Chem.* Lett., 6, 143 (2017); <u>https://doi.org/10.5267/j.ccl.2017.7.001</u>